Rabeprazole
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1999
- First approval year
- 1999
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Rabeprazole
- Molecular weight
- 359.45
- Structure (SMILES)
- COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[nH]2)c1C
- Current proton pump inhibitor (PPI)
- current proton pump inhibitor ppi
- e 3810 ppi
- E-3810 (PPI)
- e3810
- E3810
- eraloc
- Eraloc
- ly 307640
- Ly-307640
- ly307640
- LY307640
- one proton pump inhibitor ppi
- one proton pump inhibitor(PPI)
- pariprazole
- Pariprazole
- ppi
- PPI (proton pump inhibitor)
- ppi 20 mg domperidone 10 mg
- ppi proton pump inhibitor
- Proton Pump Inhibitor (PPI) Therapy
- proton pump inhibitor ppi
- proton pump inhibitor ppi therapy
- proton pump inhibitors ppi
- rabeprazol
And 19 more, listed on the interactive page.
- CAS registry numbers
- 117976-89-3
- ChEMBL ID
- CHEMBL1219
- InChIKey
- YREYEVIYCVEVJK-UHFFFAOYSA-N
- PubChem compound IDs
- 5029
- RxNorm IDs (RxCUI)
- 114979
- FDA ingredient codes (UNII)
- 32828355LL
- A02BC04
- A02BC54
Sources for recorded values
- Applicant
- WAYLIS THERAP
- Approval date
- 19 Aug 1999
- Application number
- NDA020973
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- United States (FDA)
- Approved
- Pharmacology name
- rabeprazole
- Type
- Synthetic organic
- Drug name stem
- -prazole
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
Open Targets mechanisms
- Mechanism
- Potassium-transporting ATPase inhibitor
- Action type
- Inhibitor
- Target
- Potassium-transporting ATPase
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- ATP4A|ATP4B
- Protein identifier
- P20648|P51164
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Lymphoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Hematologic Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001642
- Subject identifier
- D019337
- Condition
- Gastroesophageal Reflux
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003948
- Subject identifier
- D005764
- Condition
- Duodenal Ulcer
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004607
- Subject identifier
- D004381
- Condition
- Communicable Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0005741
- Subject identifier
- D003141
- Condition
- Dyspepsia
- Highest recorded phase
- 2
- Condition identifier
- EFO:0008533
- Subject identifier
- D004415
- Condition
- Helicobacter Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:1000961
- Subject identifier
- D016481
- Condition
- Cholangiocarcinoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:1001961
- Subject identifier
- D018281
- Condition
- Gastrointestinal Hemorrhage
- Highest recorded phase
- 3
- Condition identifier
- HP:0002239
- Subject identifier
- D006471
- Condition
- Peptic Ulcer
- Highest recorded phase
- 4
- Condition identifier
- HP:0004398
- Subject identifier
- D010437
- Condition
- Amyotrophic Lateral Sclerosis
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004976
- Subject identifier
- D000690
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition identifier
- EFO_0000771
- Condition identifier
- EFO_0001642
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003948
- Condition identifier
- EFO_0004607
- Condition identifier
- EFO_0005741
- Highest recorded phase
- 1
- Condition identifier
- EFO_0005769
- Condition identifier
- EFO_0008533
- Highest recorded phase
- 2
- Condition identifier
- EFO_0009454
- Condition identifier
- EFO_1000961
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001355
- Highest recorded phase
- 2
- Condition identifier
- HP_0002239
- Highest recorded phase
- 3
- Condition identifier
- HP_0004398
- Condition identifier
- HP_0004398
- Highest recorded phase
- 4
- Condition identifier
- HP_0100749
- Condition identifier
- MONDO_0001126
- Condition identifier
- MONDO_0002268
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004247
- Condition identifier
- MONDO_0004247
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0004976
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004979
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005068
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005113
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005412
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0006781
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0006896
- Highest recorded phase
- 3
And 1 more, listed on the interactive page.
- Event
- abdominal discomfort
- Reports
- 43
- Reporting signal score
- 26.9726
- Event
- anorectal discomfort
- Reports
- 10
- Reporting signal score
- 25.5295
- Event
- asthma
- Reports
- 66
- Reporting signal score
- 84.1835
- Event
- autoimmune haemolytic anaemia
- Reports
- 11
- Reporting signal score
- 24.2048
- Event
- bacterial infection
- Reports
- 32
- Reporting signal score
- 67.6241
- Event
- bronchial secretion retention
- Reports
- 10
- Reporting signal score
- 37.2526
- Event
- clumsiness
- Reports
- 17
- Reporting signal score
- 57.6161
- Event
- colitis microscopic
- Reports
- 26
- Reporting signal score
- 74.5808
- Event
- drug withdrawal syndrome neonatal
- Reports
- 18
- Reporting signal score
- 34.7633
- Event
- enterocolitis haemorrhagic
- Reports
- 16
- Reporting signal score
- 50.2326
- Event
- eosinophil count increased
- Reports
- 44
- Reporting signal score
- 122.756
- Event
- eosinophilic bronchitis
- Reports
- 32
- Reporting signal score
- 203.456
- Event
- fall
- Reports
- 83
- Reporting signal score
- 29.9938
- Event
- flatulence
- Reports
- 22
- Reporting signal score
- 24.3218
- Event
- full blood count abnormal
- Reports
- 13
- Reporting signal score
- 33.5646
- Event
- gait spastic
- Reports
- 13
- Reporting signal score
- 61.8915
- Event
- gastric polyps
- Reports
- 26
- Reporting signal score
- 93.8721
- Event
- gastrooesophageal reflux disease
- Reports
- 87
- Reporting signal score
- 153.266
- Event
- hepatic function abnormal
- Reports
- 27
- Reporting signal score
- 24.5821
- Event
- hypertonic bladder
- Reports
- 16
- Reporting signal score
- 51.9531
- Event
- hypocalcaemia
- Reports
- 59
- Reporting signal score
- 122.357
- Event
- hypokalaemia
- Reports
- 50
- Reporting signal score
- 60.253
- Event
- hypomagnesaemia
- Reports
- 78
- Reporting signal score
- 210.061
- Event
- hyponatraemia
- Reports
- 43
- Reporting signal score
- 33.9345
- Event
- hypoparathyroidism secondary
- Reports
- 10
- Reporting signal score
- 50.6858
And 26 more, listed on the interactive page.
- NCT00165841
- NCT00222170
- NCT00237367
- NCT00251732
- NCT00304421
- NCT00464308
- NCT00539240
- NCT00787891
- NCT00838526
- NCT00839306
- NCT00857597
- NCT01136317
- NCT01391715
- NCT02135107
- NCT04494243
- NCT04622358
- NCT01089543
- NCT01513785
- NCT01398410
- NCT02847455
- NCT04215653
- NCT01408186
- NCT01805934
- NCT02767479
- NCT01954043
And 8 more, listed on the interactive page.
- Dose
- 20mg
- Route
- Oral
- How often
- Once daily
- Do not chew, crush or split tablets
- Swallow whole
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 1
- Polar surface area
- 83.09
- Calculated partition coefficient (ALogP)
- 2.99
- Calculated partition coefficient (XLogP)
- 1.9
- Prodrug
- No
- Chirality
- Racemic
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 8
- Heavy atoms
- 25
- Molecular formula
- C18H21N3O3S
- Monoisotopic mass
- 359.13036271
- Natural product
- Yes
- Recorded assays
- 1,044
- Active assays
- 37
- Confirmatory
- Screening
- Anti-Ulcer Agents
- Proton Pump Inhibitors
Solubility
- Median
- 1,000,000
- Mean
- 1,000,000
- Minimum
- 1,000,000
- Maximum
- 1,000,000
- Unit
- nM
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- Solubility
Related records
Trials (151)
- 14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy
- A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet
- A Bioequivalence Study of Idiazole 20mg DR Tabs and PARIET® 20 mg DR Tabs After a Single Oral Dose Administration Under Fasting Conditions in Healthy Adults
- A Bioequivalence Study of Rabeprazole From Idiazole 20mg DR Tabs (GSK, Egypt) and PARIET 20 mg DR Tabs (JANSSEN, EGYPT)
- A Clinical Trial of Anaprazole for Treating Reflux Esophagitis.
- A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014)
- A Comparative Study of Proton-pump Inhibitor Tests for Chinese Reflux Patients in Relation to the CYP2C19 Genotypes
- A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease
- A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients
- A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of Vismodegib
- A Multiple Ascending High Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
- A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors
- A Phase 3 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.
- A Pilot Cross-over Bioequivalence Study of E3810 for Healthy Japanese Male (Under Postprandial Condition)
- A Pilot Study of a 14-day Modified Sequential Therapy for Helicobacter Pylori Infection
- A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of Palbociclib
- A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations
- A Study of E3810 for Japanese Subjects With Functional Dyspepsia (SAMURAI Study: Suppression of Acid Milieu With Rabeprazole Improving Functional Dyspepsia ) (Study E3810-J081-204)
- A Study of Efficacy and Safety of "On-demand" Maintenance Therapy With Rabeprazole in Patients With Non-erosive Reflux Disease (NERD)
- A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis
Approved for (3)
- Bacterial infectious disease
- Gastroesophageal reflux disease
- Peptic ulcer disease
In development for (13)
- Amyotrophic lateral sclerosis Phase 1
- Asthma Phase 3
- Cancer Phase 1
- Duodenal ulcer Phase 3
- Dyspepsia Phase 2
- Helicobacter pylori infectious disease Phase 3
- Infectious disease Phase 1
- Intrahepatic cholangiocarcinoma Phase 1
- Lymphoid neoplasm Phase 1
- Lymphoma Phase 1
- Myocardial infarction Phase 1
- Neoplasm Phase 1
- Peptic esophagitis Phase 3
Other linked conditions (2)
- Calcium metabolic disease
- Gastric ulcer